We have previously established an in silico classification method ("CPathPred") to predict the major clearance pathways of drugs based on an empirical decision with only four physicochemical descriptors, charge, molecular weight, log D, and protein unbound fraction in plasma, using a rectangular method. In this study, we attempted to improve the prediction performance of the method by introducing a support vector machine (SVM) and increasing the number of descriptors. The dataset consisted of 141 approved drugs whose major clearance pathways were classified into metabolism by CYP3A4, CYP2C9 or CYP2D6, OATP-mediated hepatic uptake or renal excretion.
Introduction
It is crucial to identify drug candidates that are not likely to succeed as early as possible because the cost per drug approval increases enormously as candidates progress to late clinical development phases. As one of the important measures for good drugs, the pharmacokinetic properties of drug candidates were intensively investigated to select promising compounds possessing "drug-likeness" in the drug discovery stage and to understand the possible cause of inter-individual variability in the pharmacological/toxicological effects of drugs (Lipinski et al., 2001 ). In particular, it is inevitable to understand the molecules responsible for drug elimination and the relative contribution of each clearance pathway to the overall total clearance of drugs to forecast the quantitative risk of drug-drug interactions (DDIs) or genetic polymorphisms of certain metabolic enzymes/transporters. Various methods for such purpose have been proposed (Emoto et al., 2010; Yoshida et al., 2013) , however, because combination of several experiments with significant cost and labor are required, it is almost impossible to perform such experiments in the early stage of drug discovery. Alternatively, in recent years, several types of in silico structure-based and ligand-based drug design approaches have extensively applied to the various aspects of drug discovery such as the prediction of substrate specificity of each enzyme/transporter and metabolic sites and the clearance of each drug from the physicochemical properties calculated on the basis
6 of chemical structures (van de Waterbeemd and Gifford, 2003; Lewis and Ito, 2010) .
Although some in silico prediction methods were established in accordance with the principles of theoretical physics, there are also some well-known empirical prediction methods created on the basis of the experience and intuition of experts in the field of pharmaceutical sciences such as Lipinski's rule of five (Lipinski et al., 2001) . Wu et al.
expanded the basic concept of the biopharmaceutics classification system (Yu et al., 2002) and proposed a biopharmaceutics drug disposition classification system to clearly predict the involvement of metabolic enzymes and transporters in the total clearance of drugs (Wu and Benet, 2005) . This type of approach helps us to approximately understand the pharmacokinetic properties of drugs. There are several in silico methods to predict whether a compound is susceptible to a certain metabolic enzyme (Yamashita et al., 2008; Mishra et al., 2010; Cheng et al., 2012) , but it is fairly difficult to identify the major clearance pathways of drugs in humans because multiple elements such as metabolic clearance mediated by various enzymes should be correctly predicted on the basis of the theoretical approach such as the relative activity factor (RAF) method (Venkatakrishnan et al., 2000) . Therefore, we previously established an in silico empirical classifier using a rectangular method ("CPathPred") to predict the major clearance pathways of drugs with only four physicochemical parameters easily predicted from their molecular structures (charge, molecular weight [MW] , lipophilicity
In this study, to compare the prediction performance of different systems based on 10-fold cross validation, the effect of introducing SVMs with an increased number of descriptors on the predictability of major clearance pathways of drugs in humans was verified, and ultimately, a better prediction system was proposed in comparison to the previous rectangular-based predictor.
Materials and Methods
Dataset
We used the same dataset as our previous study 12 . First, a dataset was created using the Appendix of Goodman and Gilman's The Pharmacological Basis of Therapeutics (Benet et al., 1996; Thummel and Shen, 2001; Thummel et al., 2006 ) with the addition of major OATP substrates. Information concerning clearance pathways in humans was collected from the published data. Pharmacokinetic profiles after intravenous administration and in vitro data on metabolism of drugs were also collected. The definition of the "major" clearance pathway is that a certain clearance pathway is considered to contribute to more than 50 % of the total body clearance of drugs. Of the 294 drugs listed, 141 drugs that met the criteria for the following major clearance
The drugs were then categorized by charge at neutral pH into the two following groups: 
In each SVM, it is necessary to optimize 
where TP, FP, and FN are the numbers of true-positive, false-positive, and false-negative predictions, respectively.
As an SVM classifies data into only two classes, five independent SVM-based classifiers that corresponded to each clearance pathway were prepared. Thus, the model is similar to the one-versus-the-rest method (Hsu and Lin, 2002 ), but we take multiple positives rather than choosing only an argument of the maximum. As each SVM corresponding to a specific clearance pathway independently tells us whether a compound is mainly eliminated via a specified pathway ("Yes" or "No") in our current system, our prediction system is allowed to conclude that a compound has no major clearance pathway or multiple major clearance pathways.
It is not appropriate to train an SVM only with a direct input of data for 141 drugs, as the drugs were not uniformly distributed among the clearance pathways (Table   1 ). Thus, we adopted a random oversampling technique (Liu et al., 2006) . In the random oversampling process, we increased the number of examples in the minority class by replicating data randomly. We evaluated SVM by 10-fold cross validation, which tests trained classifiers with subdivided test data within training dataset. Briefly,
1 2 a sample of data partitioned into 10 subsets and a model was trained using 9 subsets.
Then validation was performed on the model using the remaining 1 subset. In our analysis, to further reduce the fluctuation of outcomes caused by a random selection of subsets, 10 rounds of cross-validation were performed using different partitions, and the validation results were averaged over the rounds.
The procedure of training an SVM with random oversampling and evaluating the SVM by 10-fold cross validation is as follows ( Each SVM would yield the distance of a test compound from the borderline.
Ten-fold cross validation was repeated 10 times, and a final prediction result was determined as the average of 300 SVM outputs for each drug. If a test compound is located in the incorrect territory, then the distance was yielded as a negative numeral.
A compound would be considered belonging to a certain clearance pathway if the averaged distance of the 300 SVMs for the corresponding clearance pathway was positive.
Feature selection of descriptors based on the greedy algorithm
We constructed three types of predictors using SVMs with only default descriptors ("default descriptor SVM"), SVMs with the default descriptors and the 881 descriptors ("885 descriptor SVM"), and the SVMs with the default descriptors and the feature-selected descriptors from the 881 descriptors ("feature selection SVM"). To incorporate the most relevant descriptors and consequently increase the accuracy, we performed feature selection using the greedy algorithm (Caruana and Freitag, 1994) , as theoretically, there are 2 881 combinations of input data, making it impossible to investigate all possible combinations in an exhaustive manner.
The process of feature selection based on the greedy algorithm is as follows predictor as previously explained; (4) Repeat the aforementioned procedures for all 881 descriptors to verify which descriptor was associated with the maximum F-measure;
(5) Add the aforementioned descriptor to the default descriptors; and (6) Repeat the aforementioned procedure until the F-measure was not further improved by the addition of the descriptor selected in step (5).
Prediction performance of the entire predictor
Prediction performance of the entire predictor for five clearance pathways was evaluated using two criteria, accuracy and overall precision, which were calculated using equations (5) a specified clearance pathway of more than 6 of 10 times.
Validation of the effectiveness of feature selection based on the greedy algorithm
To confirm whether the prediction accuracy according to feature selection based on the greedy algorithm is superior to that performed by random feature selection, the prediction performance of 1.0 × 10 7 predictors with random feature selection was evaluated by 10-fold cross-validation. Then, the probability density distribution of the accuracy in 1.0 × 10 7 predictors constructed with the random feature selection was calculated.
To confirm that the significance of the feature selection based on the greedy algorithm is not likely to occur by chance, we compared the accuracy of 1.0 × 10 7 predictors prepared by random feature selection with that of the "feature selection
SVM." Figure 3 shows the histogram of the probability density distribution of the accuracy in 1.0 × 10 7 predictors constructed with the random feature selection.
Discussion
In this study, we succeeded in improving the prediction performance of an in silico classification method to predict the major clearance pathways of drugs by identifying the multi-dimensional boundaries of molecular descriptors calculated from chemical structures using SVMs and feature selection based on the greedy algorithm compared with our previous rectangular method ( Kusama et al., 2010) . Moreover, we confirmed that improved prediction performance could be realized using our current descriptor selection method compared to random feature selection.
The rectangular method mainly focuses on empirical knowledge and intuitiveness. However, because it required a heavy calculation, some difficulties were encountered when the number of clearance pathways to be predicted was expanded or the number of parameters used for prediction was expanded. Concerning the algorithms used for such predictors, SVM was found to be superior to a rectangular method, which uses linear boundaries, whereas SVM uses non-linear boundaries for classification. In silico prediction software (PreADMET) can generate a large number of physicochemical parameters in addition to the four default descriptors we employed in the rectangular-based predictor, and we aimed to include these parameters as well as other structural information. The greedy algorithms tend to yield local optimal solutions, but it is a rapid method. This greedy algorithm-based feature selection was
one of the most appropriate means because we repeatedly performed the learning process, which is time consuming (12 min per SVM). Some of the selected descriptors based on the greedy algorithm were associated with VDW surface area and lipophilicity (Table 3) The probability density of accuracy of 1.0 × 10 7 predictors prepared by random feature selection exhibited a bimodal distribution with a mode of 0.57, which is similar to that of the "default descriptor SVM" (0.60). This indicated that random feature selection did not result in improved prediction performance. Conversely, the accuracy of the "feature-selected SVM" was 0.87, which suggests that it is an outlier in the probability density distribution of the accuracy in 1.0 × 10 7 predictors constructed using
2 0 random feature selection, and thus, feature selection based on the greedy algorithm effectively contributes to the improvement of prediction performance.
As a future perspective, we must first expand the number of predictable clearance pathways. In addition to the five clearance pathways targeted in this research, CYP1A2, CYP2C8, CYP2C19, and glucuronide conjugation are recognized as other important clearance pathways, and they will be included in our predictor.
However, it is difficult to accomplish satisfactory learning with a small number of training data. Under such a situation, it may be necessary to improve the algorithm by excluding unnecessary data that makes classification boundaries indistinct (Tomek,
1976) and by introducing the distribution correction (Sugiyama and Muller, 2005).
Second, we need to carefully assess the possibility of overlearning. Overlearning is also called overfitting in which a learning system excessively fits its learning data, resulting in suboptimal predictions for new external data. This occurs when the learning procedure becomes longer because the machine starts to memorize the data and not learn from it or when the learning data is atypical. Random oversampling tends to cause overlearning due to training for several copied data (Batista et al., 2004) .
Because there are more negative answers than positive ones regarding clearance pathway prediction, oversampling will be likely to occur for positive data. This may result in an increased number of false-negative predictions. To mitigate overfitting, we
2 1 performed 10-fold cross-validation 10 times, but further verification could be provided using external data.
In future, we must also account for the drugs cleared by multiple clearance pathways, as 39 of 230 drugs were found to be cleared through multiple clearance pathways in our dataset. Regulatory guidance from FDA and EMA stated that if the contribution of a clearance pathway was more than 25%, sponsors were encouraged to test the effect of inhibitors for that pathway on the pharmacokinetics of that drug (EMA, 2010; FDA, 2012) .
Although there are in vitro data on individual enzymes and transporters, there are little data on the overall clearance pathways in humans. Clearance pathway determination is important for assessing pharmacokinetic variability in the clinical setting. However, the fact that we could collect data for only 141 drugs for our dataset indicates that such data are not readily available. Moreover, investigations on transporters have only been conducted for recently developed drugs. In such cases, industrial scientists, as well as regulatory and clinical scientists, can utilize this prediction system to evaluate the pharmacokinetic properties of a compound.
In conclusion, we developed a highly accurate in silico prediction system for major clearance pathways of drugs based on SVM and a feature selection based on the greedy algorithm. This method will enable drug discovery researchers to predict See "Construction of prediction systems using SVM" section in "Materials and
Methods" for details.
Fig. 2 Schematic diagram of a feature selection based on a greedy algorithm
See "Feature selection of descriptors based on the greedy algorithm" section in "Materials and Methods" for details. Tables   Table 1 Drug 
